Sopharma AD notifies that for September 2015 the Company recorded a decrease of sales revenues of 35% compared to the same month of 2014, including 1% increase of domestic sales and 48% decrease of export sales.

For the first nine months of this year, revenues from sales decreased by 18% compared to the same period of 2014, including 2% increase of domestic sales and a 27% decrease of export sales.

Sopharma AD (the “Company”) notifies that on 30 September 2015 Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Momina Krepost AD, Veliko Tarnovo, Str. Magistralna 23, UIC 104055543, hereinafter referred to as "transferring company" signed a Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA), as a result of which all assets of Momina Krepost AD shall be transferred to Sopharma AD and the latter shall become its legal successor.

Sopharma AD (the “Company”) announces that on 22 October 2015 the Company bought 3 080 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 66.72%.

Sopharma AD notifies that for October 2015 the Company recorded same level of sales revenues compared to the same month of 2014, including 2% increase of domestic sales and 2% decrease of export sales.

For the first ten months of this year, revenues from sales decreased by 16% compared to the same period of 2014, including 2% increase of domestic sales and a 25% decrease of export sales.

Sopharma AD notifies that for November 2015 the Company recorded a decrease of sales revenues of 5% compared to the same month of 2014, including 3% increase of domestic sales and 9% decrease of export sales.

For the first eleven months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 2% increase of domestic sales and a 23% decrease of export sales.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 18 October 2012 up to and including 24 October 2012 the Company bought 1100 own shares representing 0.00083% of the share capital of the Company, to the total value of BGN 2610.70 on the Bulgarian Stock Exchange. The average price per share was BGN 2.37.

The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.

The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 29 October 2012 was signed a merger agreement between Bulgarian Rose – Sevtopolis AD (merging company) and Sopharma AD (acquiring company). The agreement settles both the technical process of the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD, as well as the ensuing consequences for the two companies. The fair price of the shares of the companies involved in the transformation is determined based on generally accepted valuation methods.

The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 29 October 2012 was signed a merger agreement between Sopharma AD and Bulgarian Rose – Sevtopolis AD. The agreement settles both the technical process of the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD, as well as the ensuing consequences for the two companies. The contract and the accompanying documentation have been submitted to the Financial Supervision Commission.

SOPHARMA AD (the “Company”) hereby informs that from 30 January 2014 up to and including 5 February 2014 the Company bought 6 886 own shares representing 0.005% of the share capital of the Company, to the total value of 27 221.75 BGN on the Bulgarian Stock Exchange, the average price per share was 3.95 BGN and sold 511 589 own shares representing 0.39% of the share capital of the Company, to the total value of 2 174 003.21 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.